Phase I trial of an orally available ubiquitin protein ligase inhibitor as a potential therapy for cancer.
Latest Information Update: 21 Jan 2015
At a glance
- Drugs Ubiquitin protein ligase inhibitor Daiichi Sankyo/Rigel Pharmaceuticals (Primary)
- Indications Cancer
- Focus Adverse reactions; First in man
- Sponsors Daiichi Sankyo Company
Most Recent Events
- 21 Jan 2015 New trial record